Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score.
Br J Cancer
; 105(9): 1342-5, 2011 Oct 25.
Article
em En
| MEDLINE
| ID: mdl-21970880
ABSTRACT
BACKGROUND:
Immunohistological assessment of Ki 67 expression is less expensive than Oncotype Dx, which is currently used to identify patients with lymph node-negative breast cancer, who will benefit from adjuvant chemotherapy.METHODS:
The relationship of immunohistologically measured Ki 67 to Oncotype DX recurrence score (RS) was examined in 53 cases of T1-2 N0 M0 (oestrogen receptor-positive, HER2/neu negative) breast cancer.RESULTS:
There was a strong linear correlation between Ki 67 value and the Oncotype Dx RS. All patients in the low Ki 67 group (Ki 67 of ≤ 10%) had Oncotype Dx RSs of low or intermediate risk. The vast majority of patients (93.8%) in the high-Ki 67 group (Ki 67 ≥ 25%) had oncotype RSs of high or intermediate risk.CONCLUSION:
Ki 67 proliferation value is a major, but not the sole determinant of Oncotype Dx score.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Recidiva
/
Neoplasias da Mama
/
Antígeno Ki-67
/
Perfilação da Expressão Gênica
Tipo de estudo:
Prognostic_studies
Limite:
Female
/
Humans
Idioma:
En
Revista:
Br J Cancer
Ano de publicação:
2011
Tipo de documento:
Article
País de afiliação:
Canadá